User profiles for Yasaman Barekatain
 | Yasaman BarekatainMD Anderson Cancer Center Verified email at mdanderson.org Cited by 165 |
[HTML][HTML] Homozygous MTAP deletion in primary human glioblastoma is not associated with elevation of methylthioadenosine
Homozygous deletion of methylthioadenosine phosphorylase (MTAP) in cancers such as
glioblastoma represents a potentially targetable vulnerability. Homozygous MTAP-deleted cell …
glioblastoma represents a potentially targetable vulnerability. Homozygous MTAP-deleted cell …
An enolase inhibitor for the targeted treatment of ENO1-deleted cancers
Inhibiting glycolysis remains an aspirational approach for the treatment of cancer. We have
previously identified a subset of cancers harbouring homozygous deletion of the glycolytic …
previously identified a subset of cancers harbouring homozygous deletion of the glycolytic …
KRASG12D inhibition reprograms the microenvironment of early and advanced pancreatic cancer to promote FAS-mediated killing by CD8+ T cells
…, H Sugimoto, KA Arian, H Ying, Y Barekatain… - Cancer Cell, 2023 - cell.com
The KRAS G12D mutation is present in nearly half of pancreatic adenocarcinomas (PDAC).
We investigated the effects of inhibiting the KRAS G12D mutant protein with MRTX1133, a …
We investigated the effects of inhibiting the KRAS G12D mutant protein with MRTX1133, a …
Antimicrobial prodrug activation by the staphylococcal glyoxalase GloB
With the rising prevalence of multidrug resistance, there is an urgent need to develop novel
antibiotics. Many putative antibiotics demonstrate promising in vitro potency but fail in vivo …
antibiotics. Many putative antibiotics demonstrate promising in vitro potency but fail in vivo …
Oncogenic KrasG12D specific non-covalent inhibitor reprograms tumor microenvironment to prevent and reverse early pre-neoplastic pancreatic lesions and in combination with …
…, H Sugimoto, KA Arian, H Ying, Y Barekatain… - bioRxiv, 2023 - biorxiv.org
Pancreatic ductal adenocarcinoma (PDAC) is associated with mutations in Kras, a known
oncogenic driver of PDAC; and the KRAS G12D mutation is present in nearly half of PDAC …
oncogenic driver of PDAC; and the KRAS G12D mutation is present in nearly half of PDAC …
Prodrugs of a 1-Hydroxy-2-oxopiperidin-3-yl Phosphonate Enolase Inhibitor for the Treatment of ENO1-Deleted Cancers
…, K Arthur, S Khadka, Y Barekatain… - Journal of Medicinal …, 2022 - ACS Publications
Cancers harboring homozygous deletion of the glycolytic enzyme enolase 1 (ENO1) are
selectively vulnerable to inhibition of the paralogous isoform, enolase 2 (ENO2). A previous …
selectively vulnerable to inhibition of the paralogous isoform, enolase 2 (ENO2). A previous …
Structure-guided microbial targeting of antistaphylococcal prodrugs
Carboxy ester prodrugs are widely employed to increase oral absorption and potency of
phosphonate antibiotics. Prodrugging can mask problematic chemical features that prevent …
phosphonate antibiotics. Prodrugging can mask problematic chemical features that prevent …
[HTML][HTML] Impaired anaplerosis is a major contributor to glycolysis inhibitor toxicity in glioma
S Khadka, K Arthur, Y Barekatain, E Behr… - Cancer & …, 2021 - Springer
Background Reprogramming of metabolic pathways is crucial to satisfy the bioenergetic and
biosynthetic demands and maintain the redox status of rapidly proliferating cancer cells. In …
biosynthetic demands and maintain the redox status of rapidly proliferating cancer cells. In …
Quantification of Phosphonate Drugs by 1H–31P HSQC Shows That Rats Are Better Models of Primate Drug Exposure than Mice
Y Barekatain, S Khadka, K Harris, J Delacerda… - Analytical …, 2022 - ACS Publications
The phosphonate group is a key pharmacophore in many antiviral, antimicrobial, and
antineoplastic drugs. Due to its high polarity and short retention time, detecting and quantifying …
antineoplastic drugs. Due to its high polarity and short retention time, detecting and quantifying …
[HTML][HTML] Targeting host glycolysis as a strategy for antimalarial development
…, YH Lin, JA Reisz, R Culp-Hill, Y Barekatain… - Frontiers in Cellular …, 2021 - frontiersin.org
Glycolysis controls cellular energy, redox balance, and biosynthesis. Antiglycolytic therapies
are under investigation for treatment of obesity, cancer, aging, autoimmunity, and microbial …
are under investigation for treatment of obesity, cancer, aging, autoimmunity, and microbial …